$ENTA
ENANTA PHARMACEUTICALS INC

2015 Q3 Form 10-K Financial Statement

#000119312515401602 Filed on December 11, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q3 2014 Q2
Revenue $14.42M $2.637M $42.05M
YoY Change 446.68% 95.48% 2450.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.690M $2.760M $2.600M
YoY Change 33.7% 57.71% 45.25%
% of Gross Profit
Research & Development $7.050M $5.200M $4.553M
YoY Change 35.58% 20.93% 12.73%
% of Gross Profit
Depreciation & Amortization $200.0K $110.0K $90.00K
YoY Change 81.82% 57.14% 50.0%
% of Gross Profit
Operating Expenses $10.74M $7.960M $4.553M
YoY Change 34.92% 31.57% 12.73%
Operating Profit $34.90M
YoY Change -935.21%
Interest Expense $510.0K $240.0K $5.000K
YoY Change 112.5% -7.69% -28.57%
% of Operating Profit 0.01%
Other Income/Expense, Net $509.0K $236.0K $36.00K
YoY Change 115.68% -8.53% -10.0%
Pretax Income $4.180M -$5.090M $34.93M
YoY Change -182.12% 14.64% -944.15%
Income Tax $1.629M $48.00K $15.12M
% Of Pretax Income 38.97% 43.29%
Net Earnings $5.812M -$5.042M $50.05M
YoY Change -215.27% 13.48% -1309.59%
Net Earnings / Revenue 40.32% -191.2% 119.03%
Basic Earnings Per Share $0.30 -$0.27 $2.70
Diluted Earnings Per Share $0.29 -$0.27 $2.61
COMMON SHARES
Basic Shares Outstanding 18.71M shares 18.58M shares 18.53M shares
Diluted Shares Outstanding 19.20M shares

Balance Sheet

Concept 2015 Q3 2014 Q3 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $145.2M $90.80M $95.90M
YoY Change 59.91% -10.54% 1.48%
Cash & Equivalents $21.73M $30.70M $26.37M
Short-Term Investments $123.5M $60.10M $69.50M
Other Short-Term Assets $9.700M $12.70M $13.20M
YoY Change -23.62% 693.75% 780.0%
Inventory
Prepaid Expenses
Receivables $15.29M $1.724M $399.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $170.6M $108.0M $111.7M
YoY Change 58.04% 3.12% 14.11%
LONG-TERM ASSETS
Property, Plant & Equipment $5.886M $1.803M $1.551M
YoY Change 226.46% 60.84% 34.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $64.20M $41.00M $41.70M
YoY Change 56.59% 283.18% 106.44%
Other Assets $5.200M $4.600M $4.600M
YoY Change 13.04% 1050.0% 1050.0%
Total Long-Term Assets $75.37M $47.44M $47.84M
YoY Change 58.88% 286.95% 119.38%
TOTAL ASSETS
Total Short-Term Assets $170.6M $108.0M $111.7M
Total Long-Term Assets $75.37M $47.44M $47.84M
Total Assets $246.0M $155.4M $159.5M
YoY Change 58.29% 32.86% 33.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.543M $1.874M $1.284M
YoY Change -17.66% 26.54% 39.87%
Accrued Expenses $3.962M $2.872M $2.984M
YoY Change 37.95% -5.37% 47.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change
Total Short-Term Liabilities $6.704M $4.746M $4.268M
YoY Change 41.26% 4.86% 45.12%
LONG-TERM LIABILITIES
Long-Term Debt $700.0K $200.0K $200.0K
YoY Change 250.0%
Other Long-Term Liabilities $1.713M $229.0K $405.0K
YoY Change 648.03% -36.21% -24.3%
Total Long-Term Liabilities $1.713M $229.0K $405.0K
YoY Change 648.03% -36.21% -24.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.704M $4.746M $4.268M
Total Long-Term Liabilities $1.713M $229.0K $405.0K
Total Liabilities $9.856M $6.761M $6.561M
YoY Change 45.78% 3.94% 24.73%
SHAREHOLDERS EQUITY
Retained Earnings $5.980M -$73.01M -$67.97M
YoY Change -108.19% -32.05% -34.01%
Common Stock $230.1M $221.8M $188.0K
YoY Change 3.78% 122423.76% 4.44%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.000K $2.000K
YoY Change 0.0% 0.0%
Treasury Stock Shares 0.000 shares 208.8K shares 208.8K shares
Shareholders Equity $236.2M $148.7M $153.0M
YoY Change
Total Liabilities & Shareholders Equity $246.0M $155.4M $159.5M
YoY Change 58.29% 32.86% 33.29%

Cashflow Statement

Concept 2015 Q3 2014 Q3 2014 Q2
OPERATING ACTIVITIES
Net Income $5.812M -$5.042M $50.05M
YoY Change -215.27% 13.48% -1309.59%
Depreciation, Depletion And Amortization $200.0K $110.0K $90.00K
YoY Change 81.82% 57.14% 50.0%
Cash From Operating Activities -$2.380M -$4.930M $35.11M
YoY Change -51.72% 96.41% -693.07%
INVESTING ACTIVITIES
Capital Expenditures -$1.580M -$490.0K -$370.0K
YoY Change 222.45% 133.33% 640.0%
Acquisitions
YoY Change
Other Investing Activities $5.680M $9.700M -$26.93M
YoY Change -41.44% -230.38% -44.08%
Cash From Investing Activities $4.090M $9.220M -$27.32M
YoY Change -55.64% -220.68% -43.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 160.0K 40.00K 470.0K
YoY Change 300.0% -66.67% -132.64%
NET CHANGE
Cash From Operating Activities -2.380M -4.930M 35.11M
Cash From Investing Activities 4.090M 9.220M -27.32M
Cash From Financing Activities 160.0K 40.00K 470.0K
Net Change In Cash 1.870M 4.330M 8.260M
YoY Change -56.81% -143.17% -114.86%
FREE CASH FLOW
Cash From Operating Activities -$2.380M -$4.930M $35.11M
Capital Expenditures -$1.580M -$490.0K -$370.0K
Free Cash Flow -$800.0K -$4.440M $35.48M
YoY Change -81.98% 93.04% -704.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18795071 shares
CY2012Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2013Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
14.00
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q1 dei Entity Public Float
EntityPublicFloat
572279471
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
-115353000
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2001000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10511000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
110468000
CY2013Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1620000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8859000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1389437 shares
CY2014Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
208816 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.39
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18594574 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18803390 shares
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
221580000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
312000
CY2014Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
153000
CY2014Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
76000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1275000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
148654000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
229000
CY2014Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
116000
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
436000
CY2014Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2014Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1786000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1874000
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1786000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2872000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73012000
CY2014Q3 us-gaap Liabilities
Liabilities
6761000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155415000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
188000
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4135000
CY2014Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
436000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4746000
CY2014Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-100000
CY2014Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1584000
CY2014Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
4198000
CY2014Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2952000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
101068000
CY2014Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15321000
CY2014Q3 us-gaap Assets
Assets
155415000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
114000
CY2014Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
131307000
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1724000
CY2014Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
2770000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1803000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
436000
CY2014Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
41003000
CY2014Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15321000
CY2014Q3 us-gaap Treasury Stock Value
TreasuryStockValue
2000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
107975000
CY2014Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
60065000
CY2014Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
30239000
CY2014Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1693000
CY2014Q3 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
11123000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1594000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30699000
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5938000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
33573000
CY2014Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
5920000
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
101168000
CY2014Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4756000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2010000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1958000
CY2015Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
18000
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
338000
CY2014Q3 enta Accrued Third Party License Fee Current
AccruedThirdPartyLicenseFeeCurrent
240000
CY2015Q3 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
200000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
229957000
CY2015Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
628000
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
371000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.58
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1576413 shares
CY2014Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
493000
CY2014Q3 enta Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2872000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1752010 shares
CY2015Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.76
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18716834 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
24.71
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
854183 shares
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
185614 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18716834 shares
CY2015Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
108000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
14641000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1622000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
236157000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2172000
CY2015Q3 us-gaap Capital Lease Obligations
CapitalLeaseObligations
598000
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1713000
CY2015Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1199000
CY2015Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
448000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
122000
CY2015Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1439000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1543000
CY2015Q3 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
73000
CY2015Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
448000
CY2015Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1439000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3962000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
5980000
CY2015Q3 us-gaap Liabilities
Liabilities
9856000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
246013000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
187000
CY2015Q3 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
93000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
68000
CY2015Q3 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
85000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2117000
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4276000
CY2015Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
4322000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6704000
CY2015Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
33000
CY2015Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1276000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2062000
CY2015Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
69000
CY2015Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
529000
CY2015Q3 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
598000
CY2015Q3 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
79000
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18852000
CY2015Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
4640000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
187717000
CY2015Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6107000
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
18399000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
21369000
CY2015Q3 us-gaap Assets
Assets
246013000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
69000
CY2015Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
209044000
CY2015Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15289000
CY2015Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
433000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5886000
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2015Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
64238000
CY2015Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6107000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
170641000
CY2015Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
123479000
CY2015Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21327000
CY2015Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3204000
CY2015Q3 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
1447000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8267000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21726000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10162000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25093000
CY2015Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
187664000
CY2015Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2903000
CY2015Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
237000
CY2015Q3 enta Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
3962000
CY2015Q3 enta Upfront License Fees Payable
UpfrontLicenseFeesPayable
350000
CY2015Q3 enta Accrued Fixed Assets Purchases
AccruedFixedAssetsPurchases
1307000
CY2015Q3 enta Future Minimum Lease Payments Due Current
FutureMinimumLeasePaymentsDueCurrent
2026000
CY2015Q3 enta Future Minimum Lease Payments Due In Two Years
FutureMinimumLeasePaymentsDueInTwoYears
2083000
CY2015Q3 enta Future Minimum Lease Payments Due In Three Years
FutureMinimumLeasePaymentsDueInThreeYears
2141000
CY2015Q3 enta Future Minimum Lease Payments Due In Four Years
FutureMinimumLeasePaymentsDueInFourYears
2202000
CY2015Q3 enta Future Minimum Lease Payments Due In Five Years
FutureMinimumLeasePaymentsDueInFiveYears
2265000
CY2015Q3 enta Future Minimum Lease Payments Due Thereafter
FutureMinimumLeasePaymentsDueThereafter
4522000
CY2015Q3 enta Future Minimum Lease Payments Due
FutureMinimumLeasePaymentsDue
15239000
CY2013Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
4.31 pure
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4600000 shares
CY2013Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
59892000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0 shares
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
10653000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M2D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0105 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.140 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-381000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.73 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.510 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.025 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.055 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9788039 shares
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9788039 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.16
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2013 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
420000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
606000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
115888000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
9627000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
559000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6569000
CY2013 us-gaap Revenues
Revenues
32053000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1063000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
59892000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
307000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
598000
CY2013 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1262000
CY2013 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-1109000
CY2013 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3540000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
9029000
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-22000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6183000
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
161808000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
161808000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-241000
CY2013 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
100000
CY2013 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-2526000
CY2013 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
26000000
CY2013 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
381000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9615000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9627000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
248000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6569000
CY2013 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
6053000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap License Costs
LicenseCosts
250000
CY2013 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5453000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1063000
CY2013 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2526000
CY2013 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
13670000
CY2013 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-147000
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4590000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
948000
CY2013 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
23024000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1652000
CY2013 us-gaap Interest Expense
InterestExpense
31000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-69216000
CY2013 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
56911000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16841000
CY2013 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
13670000
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
90000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-285000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
559000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7574000
CY2013 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
59892000
CY2013 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
41825000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
115000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
221000
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
31000
CY2013 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
1811000
CY2013 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.80
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
20179000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y22D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0189 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.022 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1.188 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.005 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.055 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
830437 shares
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.021 pure
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19185228 shares
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18354791 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
19.98
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.88
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.787 pure
CY2014 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
554000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1028000
CY2014 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
110000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
98405000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
34438000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1054000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-98000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
34438000
CY2014 us-gaap Revenues
Revenues
47741000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2682000
CY2014 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
3000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-568000
CY2014 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
1986000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
18985000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
283000
CY2014 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2120000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
916000
CY2014 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
3000
CY2014 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
40000000
CY2014 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-166000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-98000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
34340000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19268000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
467000
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
148000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
34438000
CY2014 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
7741000
CY2014 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
110000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-15170000
CY2014 us-gaap License Costs
LicenseCosts
250000
CY2014 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
8421000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
2682000
CY2014 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-130000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-13048000
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2273000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-10000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
948000
CY2014 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
28756000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
21840000
CY2014 us-gaap Interest Expense
InterestExpense
18000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
497000
CY2014 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
8000
CY2014 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1164000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18740000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
180000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-183000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
151000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1054000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10016000
CY2014 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
110000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3219000
CY2014 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
91506000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
399000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
352000
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
8000
CY2014 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-15211000
CY2014 enta Conversion Of Warrants Into Preferred Stock
ConversionOfWarrantsIntoPreferredStock
206000
CY2014 enta Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncrease
166000
CY2014 enta Valuation Allowance Deferred Tax Asset Change In Amount Decrease
ValuationAllowanceDeferredTaxAssetChangeInAmountDecrease
22892000
CY2014 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
2002000
CY2014 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.001 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.026 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.74 pure
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.09
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Nature of the Business</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Enanta Pharmaceuticals, Inc. (the &#x201C;Company&#x201D;), incorporated in Delaware in 1995, is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs primarily for the treatment of viral infections and liver diseases. The Company has developed novel protease and NS5A inhibitors for treatment of hepatitis C virus (&#x201C;HCV&#x201D;) infection. The Company also has programs to develop cyclophilin and nucleotide polymerase inhibitors targeted against HCV and also has a focus area in non-alcoholic steatohepatitis (&#x201C;NASH&#x201D;). Additionally, the Company has programs to discover new chemical entities, or compounds, for the treatment of other diseases.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the uncertainties of research and development, competition from technological innovations of others, dependence on collaborative arrangements, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance reporting capabilities.</p> </div>
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
76673000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y11D
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0185 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
41922 shares
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001177648
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
32.24
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008 pure
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P4Y
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk and of Significant Customers and Suppliers</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, accounts receivable and unbilled receivables. The Company has all cash and investment balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company has historically generated all of its revenue from its collaborative research and license agreements and a U.S. government contract (see Note 7). As of September&#xA0;30, 2015, accounts receivable and unbilled receivables consisted of amounts due from the Company&#x2019;s collaborators and under the U.S. government contract (see Note 7). As of September&#xA0;30, 2014, accounts receivable and unbilled receivables consisted solely of amounts due under the U.S. government contract.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company is completely dependent on third-party manufacturers for product supply for preclinical research activities in its non-partnered programs. In particular, the Company relies and expects to continue to rely exclusively on several manufacturers to supply it with its requirements for the active pharmaceutical ingredients related to these programs. These research programs would be adversely affected by a significant interruption in the supply of it active pharmaceutical ingredients.</p> </div>
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-347000
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19294634 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
42.36
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
621150 shares
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.003 pure
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Registrant Name
EntityRegistrantName
ENANTA PHARMACEUTICALS INC
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.94
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18673484 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.77
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, management&#x2019;s judgments of separate units of accounting and best estimate of selling price of those units of accounting within its revenue arrangements; valuation of warrants, Series&#xA0;1 nonconvertible preferred stock and stock-based awards; the useful lives of property and equipment; and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
122260 shares
CY2015 dei Trading Symbol
TradingSymbol
ENTA
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.23
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.370 pure
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
526755 shares
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2015 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
518000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2336000
CY2015 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
1814000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
196304000
CY2015 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
598000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
78992000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
726000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
133000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
78992000
CY2015 us-gaap Revenues
Revenues
160880000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5838000
CY2015 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
4000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6680000
CY2015 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-2337000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
124148000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1562000
CY2015 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
1803000
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
598000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-88186000
CY2015 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2540000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23189000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
382000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-227000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2172000
CY2015 us-gaap Maintenance Costs
MaintenanceCosts
105000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
20000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4827000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1307000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2244000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13565000
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
31000
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
34077000
CY2015 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
125000000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
172000
CY2015 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
347000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
133000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
79125000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
125455000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
968000
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
40072000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
78992000
CY2015 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
1814000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46463000
CY2015 us-gaap License Costs
LicenseCosts
200000
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
2210000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
5838000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
649000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
7371000
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1880000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1326000
CY2015 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
36732000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8973000
CY2015 us-gaap Interest Expense
InterestExpense
8000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
726000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13543000
CY2015 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1199000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
35040000
CY2015 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1814000
CY2015 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
108407000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-543000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
639000
CY2015 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
11028000
CY2015 enta Onetime License Costs
OnetimeLicenseCosts
50000
CY2015 enta Office Leases Expire
OfficeLeasesExpire
September 2022
CY2015 enta Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
5000000
CY2015 enta Loss Contingency License Agreement Milestone Payment
LossContingencyLicenseAgreementMilestonePayment
500000
CY2015 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
3042000
CY2015 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2015 enta Fixed Assets Financed By Landlord
FixedAssetsFinancedByLandlord
239000
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-5203000
CY2014Q1 us-gaap Revenues
Revenues
2160000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-76000
CY2014Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7287000
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.49
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.54
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
28753000
CY2015Q1 us-gaap Revenues
Revenues
57367000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
210000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-20018000
CY2015Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
8806000
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.61
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.70
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
50053000
CY2014Q2 us-gaap Revenues
Revenues
42051000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
36000
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15122000
CY2014Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7156000
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
2418000
CY2015Q2 us-gaap Revenues
Revenues
11599000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
287000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
428000
CY2015Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9896000
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-5370000
CY2013Q4 us-gaap Revenues
Revenues
893000
CY2013Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
87000
CY2013Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
6350000
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.18
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.26
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
42009000
CY2014Q4 us-gaap Revenues
Revenues
77498000
CY2014Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
301000
CY2014Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-28502000
CY2014Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7288000
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-5042000
CY2014Q3 us-gaap Revenues
Revenues
2637000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
236000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
48000
CY2014Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7963000
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.30
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
5812000
CY2015Q3 us-gaap Revenues
Revenues
14416000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
509000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1629000
CY2015Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
10742000

Files In Submission

Name View Source Status
0001193125-15-401602-index-headers.html Edgar Link pending
0001193125-15-401602-index.html Edgar Link pending
0001193125-15-401602.txt Edgar Link pending
0001193125-15-401602-xbrl.zip Edgar Link pending
d21127d10k.htm Edgar Link pending
d21127dex211.htm Edgar Link pending
d21127dex231.htm Edgar Link pending
d21127dex311.htm Edgar Link pending
d21127dex312.htm Edgar Link pending
d21127dex321.htm Edgar Link pending
enta-20150930.xml Edgar Link completed
enta-20150930.xsd Edgar Link pending
enta-20150930_cal.xml Edgar Link unprocessable
enta-20150930_def.xml Edgar Link unprocessable
enta-20150930_lab.xml Edgar Link unprocessable
enta-20150930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g21127g15n10.jpg Edgar Link pending
g21127g59v03.jpg Edgar Link pending
g21127g82a75.jpg Edgar Link pending
g21127g97l87.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending